Selzentry

(Maraviroc)

ApprovedSmall molecule

Maraviroc is used to treat HIV infection in patients whose virus has a specific type that the drug can block. It works by preventing HIV from entering and infecting CD4 cells, which are important for the immune system.[2] Selzentry is currently approved and in use across 15 indications[4].[1]

Selzentry is one of 393 small molecule programs targeting Viral Disease. It is currently in Approved.

Indications

108

Total Trials

Active Trials

392

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Viral DiseaseActive, not recruiting

StrokeTerminated

AtherosclerosisCompleted

MyositisNot yet recruiting

SarcoidosisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

AIDS DementiaApproved

Metastatic Colorectal CancerActive, not recruiting

Hematopoietic and Lymphoid Cell NeoplasmApproved

HIVCompleted

Viral DiseaseApproved

Active, not recruiting

StrokePhase 3

Terminated

AtherosclerosisApproved

Completed

MyositisApproved

Not yet recruiting

SarcoidosisPreclinical

Active, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

Approved

AIDS DementiaApproved

Approved

Metastatic Colorectal CancerPreclinical

Active, not recruiting

Hematopoietic and Lymphoid Cell NeoplasmApproved

Approved

HIVPhase 2

Completed

Showing 10 of 15 indications

Competition

Competitive Landscape

147 competitors in Stroke

#DrugCompanyPhaseTrials

Selzentry

GSK

Approved

4 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Stroke

NCT07080567

Q2 2028

Phase 2Recruiting

HIV

NCT06805656

Q3 2028

PreclinicalRecruiting

HIV

NCT05470491

Phase 2Recruiting

Safety and Efficacy

NCT06853223

Q3 2029

ApprovedNot yet recruiting

Myositis

NCT07668505

Clinical

Trials by Indication[1]

Treatment9 trials

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Unknown status·FFundación Huésped·Phase 4·NCT01013987·60 enrolled

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Completed·NNorthwestern University·Phase 2·NCT00993148·25 enrolled

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Completed·UUniversity of California, San Diego·Phase 4·NCT00925756·32 enrolled

Show 6 more trials

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Completed· GSK logo

GSK··NCT00850395·79 enrolled

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Completed·GGermans Trias i Pujol Hospital·Phase 3·NCT00808002·30 enrolled

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 2/3·NCT00098722·474 enrolled

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 2/3·NCT00098748·190 enrolled

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00537394·517 enrolled

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 2/3·NCT00098306·601 enrolled

Interaction5 trials

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

Completed· GSK logo

GSK·Phase 4·NCT00666705·18 enrolled

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

Completed·OOttawa Hospital Research Institute·Phase 1·NCT01894776·15 enrolled

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Completed· GSK logo

GSK·Phase 1·NCT02480894·112 enrolled

Show 2 more trials

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01290211·28 enrolled

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT01140412·14 enrolled

Tics5 trials

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT01597895·14 enrolled

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Completed· GSK logo

GSK·Phase 1·NCT02625207·47 enrolled

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Completed·—·Phase 1·NCT01627717·11 enrolled

Show 2 more trials

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

Completed·JJohns Hopkins University·Phase 1·NCT01980329·24 enrolled

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Completed· GSK logo

GSK·Phase 1·NCT01056874·12 enrolled

Recovery4 trials

Maraviroc Abacavir STudy - Effect on Endothelial Recovery

Unknown status·SS.F.L. van Lelyveld·Phase 4·NCT01389063·24 enrolled

Maraviroc Immune Recovery Study

Completed·SS.F.L. van Lelyveld·Phase 4·NCT00875368·85 enrolled

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·N/A·NCT00709111·34 enrolled

Show 1 more trial

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

Unknown status·HHospital Clinic of Barcelona·Phase 4·NCT01235013·60 enrolled

HIV4 trials

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

Completed·SSt Stephens Aids Trust·Phase 1·NCT00771823·16 enrolled

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Completed·UUniversity of Hawaii·Phase 2·NCT00987948·15 enrolled

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05470491·265 enrolled

Show 1 more trial

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Use of Antiretrovirals

Recruiting·FFederal University of São Paulo·Phase 2·NCT06805656·70 enrolled

55 more indications

HIV infection4 trials

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed·SSEARCH Research Foundation·Phase 1/2·NCT02475915·15 enrolled

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

Completed·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 1·NCT01719627·10 enrolled

Effects of Intensive cART During Acute/Early HIV Infection

Completed·UUniversity of Toronto·Phase 2/3·NCT01154673·32 enrolled

Show 1 more trial

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01505114·594 enrolled

HIV-14 trials

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 2·NCT00795444·10 enrolled

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed·FFederal University of São Paulo·N/A·NCT02961829·30 enrolled

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

Completed·AASST Fatebenefratelli Sacco·Phase 4·NCT00884858·100 enrolled

Show 1 more trial

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Completed·RRockefeller University·N/A·NCT00525733·40 enrolled

Stroke4 trials

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Recruiting·UUniversity of Calgary·Phase 2·NCT04789616·120 enrolled

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Recruiting·EEmmanuel Carrera·Phase 2·NCT07080567·80 enrolled

Maraviroc to Augment Rehabilitation Outcomes After Stroke

Terminated·UUniversity of California, Los Angeles·Phase 2/3·NCT03172026·2 enrolled

Show 1 more trial

Safety of Maraviroc for Post-stroke Depression

Completed·TTel-Aviv Sourasky Medical Center·Phase 2·NCT05932550·10 enrolled

ESS3 trials

Expanded Access Program for Maraviroc At Multiple Centers

Completed· GSK logo

GSK·Phase 3·NCT00426660·1,047 enrolled

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

No longer available· GSK logo

GSK··NCT00801515

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Completed·RRockefeller University·Phase 1·NCT00703586·8 enrolled

Itching2 trials

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00966329·30 enrolled

Switching Undetectables to Selzentry

Completed·SSt. Hope Foundation·Phase 4·NCT01866267·31 enrolled

Adult Subject2 trials

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00783484·37 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·Phase 2·NCT00764465·45 enrolled

ART2 trials

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

Completed·SSouthern California Institute for Research and Education·N/A·NCT02934022·25 enrolled

A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)

Completed·BBruce Brew·Phase 4·NCT01449006·19 enrolled

Hepatitis C2 trials

Maraviroc Efficacy for Hepatitis C

Completed·UUniversity of Maryland, Baltimore·Phase 4·NCT02881762·10 enrolled

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Withdrawn· GSK logo

GSK·Phase 4·NCT00782301

Immunodeficiency2 trials

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Completed· GSK logo

GSK·Phase 2·NCT00634959·37 enrolled

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Completed· GSK logo

GSK·Phase 2·NCT00643643·41 enrolled

Transplantation2 trials

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Unknown status·—·Phase 2·NCT02799888·40 enrolled

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation

Completed·—·Phase 1/2·NCT00948753·38 enrolled

Immune2 trials

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00944541·60 enrolled

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·N/A·NCT00988780·276 enrolled

Safety and Efficacy2 trials

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT06853223·120 enrolled

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Unknown status· GSK logo

GSK·Phase 2·NCT00791700·103 enrolled

Function2 trials

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Completed· GSK logo

GSK·Phase 4·NCT00717067·30 enrolled

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Completed·WWashington University School of Medicine·Phase 1·NCT01133210·27 enrolled

Tenofovir2 trials

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT02039323·6 enrolled

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Terminated· GSK logo

GSK·Phase 3·NCT01345630·813 enrolled

Pilot Study2 trials

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

Terminated· GSK logo

GSK·Phase 1·NCT00496782·16 enrolled

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Completed· GSK logo

GSK·Phase 2·NCT00827112·129 enrolled

COVID-192 trials

Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

Terminated·—·Phase 2·NCT04441385·60 enrolled

Maraviroc in Patients With Moderate and Severe COVID-19

Completed·RRhode Island Hospital·Phase 1·NCT04435522·9 enrolled

Labor1 trial

Maraviroc Switch Collaborative Study

Completed·KKirby Institute·Phase 4·NCT01384682·399 enrolled

Transplant Recipient1 trial

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Terminated·—·Phase 1/2·NCT02167451·31 enrolled

TED1 trial

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Completed· GSK logo

GSK·Phase 1·NCT01597648·42 enrolled

Trial1 trial

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Completed· GSK logo

GSK·Phase 3·NCT00098293·916 enrolled

Metastatic Colorectal Cancer1 trial

CCR5-blockade in Metastatic Colorectal Cancer

Completed·NNational Center for Tumor Diseases, Heidelberg··NCT01736813·12 enrolled

Endothelial Function1 trial

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

Completed·UUniversity of California, San Francisco·Phase 3·NCT00844519·52 enrolled

Immune Function1 trial

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Terminated·SSt Stephens Aids Trust·Phase 4·NCT01049204·48 enrolled

High Risk1 trial

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT04965662·139 enrolled

Microsatellite Stable1 trial

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Completed·UUniversity Hospital Heidelberg·Phase 1·NCT03274804·20 enrolled

Completed·EEmory University·Phase 1·NCT01749566·31 enrolled

Kaposi's sarcoma1 trial

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Completed·UUniversity of California, San Francisco·Phase 2·NCT01276236·13 enrolled

Hepatitis B1 trial

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Completed· GSK logo

GSK·Phase 4·NCT01327547·138 enrolled

Graft Versus Host Disease1 trial

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02208037·279 enrolled

MPA1 trial

Maraviroc Compassionate Use

Withdrawn· GSK logo

GSK·Phase 3·NCT00719823

Hemodynamic1 trial

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Completed· GSK logo

GSK·Phase 4·NCT00853840·18 enrolled

HIV-1 infection1 trial

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02778204·47 enrolled

Bone1 trial

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01400412·262 enrolled

Cognitive impairment1 trial

Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT04966429·150 enrolled

Drug1 trial

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Completed·UUniversity of California, San Francisco·Phase 4·NCT00735072·45 enrolled

Rheumatoid Arthritis1 trial

Maraviroc in Rheumatoid Arthritis

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00427934·128 enrolled

Long COVID-191 trial

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

Not yet recruiting·HHealthBio, Inc.·Phase 2/3·NCT06974084·252 enrolled

Advanced1 trial

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT01348308·407 enrolled

Neurocognitive Dysfunction1 trial

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT02519777·191 enrolled

Adolescent1 trial

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT00977756·168 enrolled

Atherosclerosis1 trial

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Completed·UUniversity Of Perugia·Phase 4·NCT03402815·22 enrolled

Oral1 trial

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00821535·12 enrolled

Prevention1 trial

Phase II Maraviroc for GVHD Prevention

Completed·—·Phase 2·NCT01785810·37 enrolled

Central Nervous System1 trial

The Maraviroc Central Nervous System (CNS) Study

Completed·IImperial College London·Phase 1·NCT00982878·13 enrolled

Hepatic steatosis1 trial

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

Completed·UUniversity College, London·Phase 2/3·NCT03129113·90 enrolled

AIDS1 trial

Maraviroc and NeuroAIDS Pathogenesis

Completed·UUniversity of Hawaii·Phase 2/3·NCT02159027·48 enrolled

AIN1 trial

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen

Completed·SSt Stephens Aids Trust·Phase 4·NCT01190293·12 enrolled

Monotherapy1 trial

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

Completed·SSt Stephens Aids Trust·Phase 4·NCT01680536·19 enrolled

ISS1 trial

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00775294·14 enrolled

Kidney Transplant1 trial

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02741323·97 enrolled

Chemotherapy1 trial

Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Terminated·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 1·NCT02486510·7 enrolled

Myositis1 trial

A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies

Not yet recruiting·CChinese University of Hong Kong·Approved·NCT07668505·10 enrolled

Unspecified4 trials

The St. Marys and The Mater Switch Study

Terminated·IImperial College London·Phase 4·NCT00981773·18 enrolled

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Completed·IImperial College London·Phase 1·NCT01348763·13 enrolled

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

Withdrawn·IInternational Partnership for Microbicides, Inc.·Phase 1·NCT01242579

Show 1 more trial

Multicenter, Safety Study Of Maraviroc

Completed· GSK logo

GSK·Phase 3·NCT00478231·209 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 6, 2007

SELZENTRY

NDA NDA022128

Nov 20, 2009

SELZENTRY

NDA NDA022128

May 27, 2010

SELZENTRY

NDA NDA022128

Oct 21, 2011

SELZENTRY

NDA NDA022128

Aug 10, 2012

SELZENTRY

NDA NDA022128

Feb 1, 2013

SELZENTRY

NDA NDA022128

Feb 14, 2013

SELZENTRY

NDA NDA022128

Mar 27, 2014

SELZENTRY

NDA NDA022128

Apr 14, 2014

SELZENTRY

NDA NDA022128

Apr 21, 2015

SELZENTRY

NDA NDA022128

Nov 4, 2016

SELZENTRY

NDA NDA022128

Nov 4, 2016

SELZENTRY

NDA NDA208984

Nov 4, 2016

SELZENTRY

NDA NDA208984

Nov 4, 2016

SELZENTRY

NDA NDA022128

Jul 18, 2018

SELZENTRY

NDA NDA022128

Oct 30, 2020

SELZENTRY

NDA NDA022128

Oct 30, 2020

SELZENTRY

NDA NDA208984

Sources

References

[1]
ClinicalTrials.gov — 108 trial records for Maraviroc. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Selzentry drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Maraviroc compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Maraviroc. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022128). U.S. Food & Drug Administration.
[6]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: C-C Chemokine Receptor Type 5 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GSK

Selzentry

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Q3 2028

Q3 2029

Trials by Indication[1]

Treatment9 trials

Interaction5 trials

Tics5 trials

Recovery4 trials

HIV4 trials

HIV infection4 trials

HIV-14 trials

Stroke4 trials

ESS3 trials

Itching2 trials

Adult Subject2 trials

ART2 trials

Hepatitis C2 trials

Immunodeficiency2 trials

Transplantation2 trials

Immune2 trials

Safety and Efficacy2 trials

Function2 trials

Tenofovir2 trials

Pilot Study2 trials

COVID-192 trials

Labor1 trial

Transplant Recipient1 trial

TED1 trial

Trial1 trial

Metastatic Colorectal Cancer1 trial

Endothelial Function1 trial

Immune Function1 trial

High Risk1 trial

Microsatellite Stable1 trial

Pregnancy1 trial

Sts1 trial

Prophylaxis1 trial

Kaposi's sarcoma1 trial

Hepatitis B1 trial

Graft Versus Host Disease1 trial

MPA1 trial

Hemodynamic1 trial

HIV-1 infection1 trial

Bone1 trial

Cognitive impairment1 trial

Drug1 trial

Rheumatoid Arthritis1 trial

Long COVID-191 trial

Advanced1 trial

Neurocognitive Dysfunction1 trial

Adolescent1 trial

Atherosclerosis1 trial

Oral1 trial

Prevention1 trial

Central Nervous System1 trial

Hepatic steatosis1 trial

AIDS1 trial

AIN1 trial

Monotherapy1 trial

ISS1 trial

Kidney Transplant1 trial

Chemotherapy1 trial

Myositis1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News